Hikma Pharmaceuticals/£HIK
1D1W1MYTD1Y5YMAX
Capital at risk
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
- Ticker
- £HIK
- Sector
- Health
- Primary listing
- LSE
- Employees
- 9,500
- Headquarters
- London, United Kingdom
- Website
- www.hikma.com
HIK Metrics
BasicAdvanced
£3.2B
11.80
£1.30
0.66
£0.62
4.03%
Price and volume
Market cap
£3.2B
Beta
0.66
52-week high
£18.65
52-week low
£11.87
Average daily volume
932K
Dividend rate
£0.62
Financial strength
Current ratio
1.981
Quick ratio
1.018
Long term debt to equity
0.691
Total debt to equity
0.771
Dividend payout ratio (TTM)
47.55%
Interest coverage (TTM)
7.01%
Profitability
EBITDA (TTM)
649.713
Gross margin (TTM)
44.05%
Net profit margin (TTM)
11.32%
Operating margin (TTM)
19.89%
Effective tax rate (TTM)
23.29%
Revenue per employee (TTM)
£266,090
Management effectiveness
Return on assets (TTM)
7.47%
Return on equity (TTM)
15.41%
Valuation
Price to earnings (TTM)
11.8
Price to revenue (TTM)
1.326
Price to book
1.31
Price to tangible book (TTM)
2.38
Price to free cash flow (TTM)
23.743
Free cash flow yield (TTM)
4.21%
Free cash flow per share (TTM)
0.646
Dividend yield (TTM)
4.03%
Growth
Revenue change (TTM)
6.31%
Earnings per share change (TTM)
5.33%
3-year revenue growth (CAGR)
7.78%
10-year revenue growth (CAGR)
7.80%
3-year earnings per share growth (CAGR)
38.62%
10-year earnings per share growth (CAGR)
7.94%
3-year dividend per share growth (CAGR)
11.52%
10-year dividend per share growth (CAGR)
10.39%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Analyst projections of the future price of Hikma Pharmaceuticals stock.
Bulls say / Bears say
First-half core operating profit rose 9% to $405 million and revenue grew 4% to $1.73 billion, beating analyst expectations, while Hikma reaffirmed its full-year 2026 outlook (Reuters)
Shares jumped 10.3% to £17.33 following H1 results—their largest daily percentage gain since September 2022—reflecting strong investor confidence in Hikma’s turnaround efforts (Reuters)
In its April 23 trading update, Hikma reiterated 2026 guidance and said it could absorb higher shipping, energy and insurance costs from the Iran war, driving shares up nearly 6% and demonstrating resilient pricing power (Reuters)
Injectables segment core operating profit declined 8% in H1 2026, with margins contracting to 27.6% from 30.0% year-on-year, indicating persistent pressure in its highest-margin division (LSE RNS)
Supply shortages due to manufacturing challenges with an in-licensing partner weighed on MENA revenue, highlighting vulnerabilities in the company’s supply chain (LSE RNS)
Basic earnings per share fell 5% to 103 cents in H1 2026, signalling earnings dilution and potential concerns around quality of earnings despite profit growth (LSE RNS)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Upcoming events
Funds containing HIK
AllGBPEURUSD
Fund name | Fund size | £HIK weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.74% |
iShares FTSE 250£MIDD | £661M | 0.72% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.19% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.19% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.18% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.